AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Protein bicaudal D homolog 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8TD16

UPID:

BICD2_HUMAN

Alternative names:

-

Alternative UPACC:

Q8TD16; O75181; Q5TBQ2; Q5TBQ3; Q96LH2; Q9BT84; Q9H561

Background:

Protein bicaudal D homolog 2 plays a pivotal role in cellular dynamics, acting as an essential adapter that links the dynein motor complex to various cargos. It enhances dynein's processivity and facilitates the interaction between dynein and dynactin. Moreover, it plays a crucial role in cellular transport mechanisms, including Golgi-ER transport, through its interaction with RAB6A and the dynein-dynactin motor complex. Its involvement in nuclear and centrosomal positioning underscores its importance in cell cycle progression.

Therapeutic significance:

Given its critical functions in cellular transport and cell cycle regulation, Protein bicaudal D homolog 2 is implicated in severe diseases such as Spinal muscular atrophy, types 2A and 2B. These conditions underscore the protein's potential as a target for therapeutic intervention, offering hope for treatments that could ameliorate or even cure these debilitating diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.